Hepatitis

While the use of direct-acting antiviral treatment for hepatitis C virus increased from 2014 to 2018, treatment rates have declined since 2019 and remain suboptimal.

It remains a challenge to understand how to stratify risk of liver diseases before they have reached the advanced stage.

Tenofovir alafenamide (Vemlidy; Gilead Science) approved for the treatment of chronic hepatitis B virus infection in pediatric patients aged 12 years and older with compensated liver disease.

Implementing screening tools, conducting brief interventions, and involving pharmacists can help manage alcohol use disorder and Alcohol Withdrawal Syndrome.

Data suggest that few US adults are aware that wine can increase the risk of cancer.

Bepirovirsen produced sustained clearance of hepatitis B virus and hepatitis B surface antigens.

Direct-acting antivirals have high efficacy for hepatitis C, however, patients with advanced liver scarring are at risk for the development of secondary diseases.

The most common cause of death for patients with non-alcoholic fatty liver disease is cardiovascular disease, but it also increases the risk of hepatocellular carcinoma and may surpass hepatitis B and C as the leading cause of this cancer.

Although fentanyl is potent and often deadly, it is not passively absorbed into the bloodstream.

Beth Macy, author of New York Times-bestselling book Dopesick and executive producer and writer on the Hulu series “Dopesick,” explains how FDA-approved drugs that treat opioid use disorder still aren’t getting into the hands of patients who need it most.

WHO has released a global plan for hepatitis B elimination by 2030, including goals to increase pediatric and maternal immunization and to improve screening and treatment.

Tenofovir alafenamide is a nucleoside analog reverse transcriptase inhibitor specifically indicated to treat HBV in adults with compensated liver disease.

The approval includes a novel dose and schedule of the combination, with a single dose of both drugs followed by durvalumab every 4 weeks in patients with unresectable hepatocellular carcinoma.

Males are more likely to suffer from the sexual dimorphism of hepatitis B infection, suggesting that sex hormones have a role in complication risk.

Investigators find that individuals with both conditions are more likely to develop severe disease than those in the control group.

The discovery of a protective antiviral protein complex could help researchers find new ways to combat hepatitis B virus.

Bulevirtide is a synthetic myristoylated peptide derived from the pre-S1 domain of the hepatitis B virus large surface protein.

Research suggests that an HIV patient’s risk of heart attack increases with each passing decade, and this risk is nearly 3-fold among patients with HIV who are also positive for hepatitis C.

Second- and third-generation individuals living in Los Angeles, California, demonstrate 35% and 61%, respectively, more of a chance of getting the disease, according to new study results.

Obesity, heavy alcohol consumption, and coagulopathy were some of the greatest risk factors associated with patients returning to the operating room within 48 hours of a surgery.

Therapeutic drug monitoring is essential with tacrolimus, which is one of the key immunosuppressive agents used after solid organ transplant.

Research indicates that there is a growing amount of unusual hepatitis cases in children throughout Europe.

Hospitalization and interprofessional team management, particularly the involvement of a pharmacist, are essential in vaccination coverage for patients with diabetes.

Climatic hazards were implicated for enhancing specific aspects of pathogens, increasing capacity of pathogens to cause more severe illness, and diminishing human capacity to cope with pathogens, such as dengue, hepatitis, pneumonia, malaria, and zika.

A P79S ORF2 variant demonstrates reduced RNA copy numbers released in the supernatant and impaired the production of infectious disease particles, investigators said.

Revised plan incorporates lessons from the COVID-19 pandemic and recent advances in technology, aligning with the Department of Health and Human Services’ roadmap.

The B-Clear study investigated the efficacy and safety of 12- or 24-weeks treatment with bepirovirsen in individuals with chronic hepatitis B.

Participants who initiated treatment with Biktarvy demonstrated superior hepatitis B virus (HBV) DNA suppression and HBV e-antigen seroconversion.